Case Study: Sterile Compounding Pharmacy Achieves NABP Accreditation After USP 797 Revision Compliance Overhaul
Situation Overview
A 503A sterile compounding pharmacy serving home infusion patients, ophthalmology practices, and pain management clinics had been operating for eight years with a strong clinical reputation but had never pursued national accreditation. Following the full implementation of the revised USP Chapter 797 standards in 2023, the pharmacy's pharmacist-in-charge conducted an internal self-assessment and recognized that several aspects of the pharmacy's operations — particularly environmental monitoring frequency, beyond-use dating documentation, and personnel competency re-evaluation intervals — did not meet the revised standards. A major health system client simultaneously notified the pharmacy that it was requiring accreditation from all compounding pharmacy suppliers within 18 months. The pharmacy engaged IHS to address the USP 797 compliance gaps and pursue NABP Compounding Pharmacy Accreditation.
Challenges
- Revised USP 797 compliance gaps: The 2023 revision of USP Chapter 797 introduced new requirements for environmental monitoring sampling locations, frequency, and action levels; updated beyond-use dating for sterile preparations; and revised personnel training and competency assessment requirements. The pharmacy's existing SOPs and monitoring programs were based on the prior USP 797 version.
- Environmental monitoring program: The pharmacy's environmental monitoring program used correct sampling methods but did not meet the revised frequency requirements for ISO 5 and ISO 7 areas under the 2023 USP 797. Historical data gaps made the transition to the new frequency schedule more complex.
- Personnel competency gaps: Two pharmacists and one technician had not completed media fill testing within the timeframe required by the revised USP 797. Gloved fingertip sampling for these individuals also needed to be repeated under the updated protocol.
- Beyond-use dating documentation: The revised USP 797 modified beyond-use dating categories and required more explicit documentation linking each compounded preparation to the specific BUD category assigned. The pharmacy's existing labeling and batch records did not include this documentation.
- VPP inspection readiness: The pharmacy had not previously undergone any third-party facility inspection and was unfamiliar with the VPP inspection process. The pharmacist-in-charge was concerned about the inspection timeline relative to the health system's 18-month deadline.
IHS Approach
IHS structured the engagement in two parallel tracks: USP 797 compliance remediation (which needed to begin immediately, before the VPP inspection) and NABP accreditation documentation development. Thomas G. Goddard, JD, PhD — IHS's principal consultant and former Chief Operating Officer and General Counsel of URAC — led the engagement directly.
USP 797 Compliance Gap Remediation
IHS conducted a line-by-line comparison of the pharmacy's existing SOPs and environmental monitoring program against the revised USP 797 requirements. Seventeen specific gaps were identified across environmental monitoring frequency, action levels, beyond-use dating documentation, personnel competency intervals, and facility qualification. A prioritized remediation plan was developed with weekly milestones.
The environmental monitoring program was revised to meet the new ISO 5 and ISO 7 sampling frequency requirements. New sampling location maps were developed consistent with USP 797's requirements. The pharmacy's environmental monitoring contractor was briefed on the revised schedule and began executing the updated program within three weeks of engagement start.
The three personnel requiring media fill and gloved fingertip re-evaluation were scheduled for assessment within the first month. All three passed on initial attempt, resolving this gap cleanly.
The pharmacy's batch record template was redesigned to include explicit BUD category documentation with the specific USP 797 provision cited for each preparation type. All active formulations were mapped to their BUD categories and the documentation was incorporated into the updated batch records.
NABP Accreditation Documentation
Concurrent with the USP 797 remediation, IHS developed the full NABP accreditation documentation package — 34 revised or new SOPs covering the compounding process from raw material receipt through patient delivery, plus quality assurance program documentation, CAPA records, and the bulk drug substance compliance assessment required by NABP's standards.
VPP Inspection Preparation
IHS conducted a full-day mock VPP inspection 10 weeks into the engagement. Two additional minor gaps were identified — an incomplete equipment calibration log for one pump and an outdated cleanroom certification certificate — both resolved within a week. The mock inspection gave the pharmacy's team confidence in the inspection process and ensured no surprises during the actual VPP visit.
VPP Inspection and Accreditation
The NABP VPP inspection occurred in month 5 of the engagement. The inspection produced one finding: a documentation format issue with the environmental monitoring log that required reformatting. IHS revised the log format and submitted the corrective action documentation within five business days. NABP granted Compounding Pharmacy Accreditation in month 7 — 11 months ahead of the health system's deadline.
Outcomes
- NABP Compounding Pharmacy Accreditation granted in month 7, well ahead of the health system's 18-month deadline
- Full USP 797 (2023 revision) compliance achieved and documented across all 17 identified gap areas
- Environmental monitoring program updated to meet revised frequency and action level requirements
- All three personnel requiring media fill and gloved fingertip re-evaluation cleared before VPP inspection
- Batch record template redesigned with explicit BUD category documentation for all active formulations
- 34 SOPs developed or substantially revised
- Only one VPP inspection finding; resolved without re-inspection
- Health system client contract renewed with expanded formulary
Key Lessons
The 2023 USP 797 revision created significant new compliance obligations for sterile compounders. Pharmacies that were fully compliant with the prior USP 797 version are not automatically compliant with the 2023 revision. The changes to environmental monitoring frequency, BUD dating categories, and personnel competency intervals are material. Every sterile compounding pharmacy should have performed a gap assessment against the 2023 revision by now; those that have not should do so before pursuing accreditation.
Environmental monitoring programs need continuous execution, not just correct design. The pharmacy in this case had correct monitoring methods but incorrect frequency. The gap was not in the method — it was in the schedule. Environmental monitoring compliance is a continuous operational discipline, not a one-time facility qualification event.
Parallel tracking compresses timelines without sacrificing quality. Running USP 797 remediation and NABP documentation development simultaneously — rather than sequentially — was the key to achieving accreditation in 7 months against an 18-month deadline. IHS structures all compounding pharmacy engagements for maximum parallel progress where the work streams are independent.
Need to Bring Your Compounding Pharmacy into Compliance and Accreditation?
IHS provides the structured consulting expertise to achieve NABP Compounding Pharmacy Accreditation, including navigating the 2023 USP 797 revision requirements. Schedule a Free Discovery Session with Thomas G. Goddard, JD, PhD — former Chief Operating Officer and General Counsel of URAC.